About Contact Us Careers

Neuraminidase Inhibitors Drug Market Size

Request Free Sample Copy

Report ID: 2563
Published Date: Dec 24, 2024
Report Format: PDF, PPT

Buy Now

Neuraminidase Inhibitors Drug Market Size

Neuraminidase Inhibitors Drug Market size was valued at USD 104.8 billion in 2024 and is set to exceed USD 249.5 billion by 2037, expanding at over 6.9% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of neuraminidase inhibitors drug is estimated at USD 110.95 billion.

This growth can be witnessed as a result of an increasing prevalence of influenza globally. Further, the advancement in the market and development of the drug is being focused upon by the companies. This will boost the market as well.

Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:

Neuraminidase Inhibitors Drug Market Size & Share, Growth Analysis 2037

Author Credits: Radhika Pawar

Report ID: 2563
Published Date: Dec 24, 2024
Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of neuraminidase inhibitors drug is estimated at USD 110.95 billion.

Neuraminidase Inhibitors Drug Market size was valued at USD 104.8 billion in 2024 and is set to exceed USD 249.5 billion by 2037, expanding at over 6.9% CAGR during the forecast period i.e., between 2025-2037.

North America industry is poised to dominate majority revenue share by 2037, as the region is highly developed since the technological advancement is rapid along with good infrastructure.

The major players in the market are F. Hoffmann La Roche, GlaxoSmithKline plc, Gilead Sciences, Daiichi Sankyo, BioCryst Ltd., and others.

Inquiry Before Buying Request Free Sample